Boeing Co vs ResMed Inc. — how do they compare? Boeing Co trades at $233.25 (market cap $183.99B), while ResMed Inc. trades at $222.39 (market cap $31.92B). The key difference: Boeing Co is far larger — about 5.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| BA | RMD | |
|---|---|---|
Market Cap | $183.99B | $31.92B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $293.73 |
52-Week Low | $179.12 | $182.82 |
Enterprise Value | $209.87B | $31.28B |
Dividend Yield | 0.03% | 1.2% |
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.
The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →